Different effects of anti-TNF-alpha biologic drugs on the small bowel macroscopic inflammation in patients with ankylosing spondylitis

Open access

Abstract

Background & Aims. Considering the ability of anti-TNF alpha drugs to lower the burden intestinal inflammation in patients with inflammatory bowel disease (IBD), and the similarity between IBD and ankylosing spondylitis (AS) regarding inflammatory intestinal involvement, we aimed to investigate the impact of anti-TNF alpha biologic therapy on subclinical intestinal inflammation in AS patients.

Methods. Between January 2008 and December 2013, 38 AS patients and 23 controls were enrolled in the study and investigated with small bowel videocapsule endoscopy examination and ileocolonoscopy. Each tertile of the small bowel (proximal, mid and distal) was assessed by calculating the Lewis score based on the image stream.

Results. The Lewis scores were significantly higher in the AS group compared to controls (580.9 ± 818 vs. 81 ± 121, p<0.001). 16 patients (42.1%) were on anti-TNF alpha therapy (Adalimumab (n = 5), Infliximab (n = 5) or Etanercept (n = 6)).31.3% of them used NSAIDs simultaneously, compared with 77.3% of the other patients (p<0.01). Their Lewis scores were lower compared to the other patients for the entire small bowel (306 ± 164 vs. 790 ± 1038, p = 0.015), its proximal and distal tertiles (238 ± 154 vs. 560 ± 543, p = 0.021, and 140 ± 189 vs. 300 ± 220, p = 0.027, respectively). The Lewis score was also lower in patients receiving Adalimumab/Infliximab compared to those on Etanercept for the entire bowel and its distal tertile (262 ± 165 vs. 380 ± 148, p = 0.069 and 62 ± 101 vs. 273 ± 236, p = 0.060, respectively).

Conclusion. Anti-TNF alpha therapy in patients with AS reduces the subclinical intestinal inflammation, but the magnitude seems to depend upon the class anti-TNF alpha agent used (Clinical Trials. gov NCT00768950).

ABBREVIATIONS(AS)

Ankylosing spondylitis

(IBD)

Inflammatory bowel disease

(TNF α)

Tumor necrosis factor alpha

(NSAIDs)

Nonsteroidal anti-inflammatory drugs

(SB)

Small bowel

(VCE)

Videocapsule endoscopy examination

(CD)

Crohn’s disease

REFERENCES

  • 1. CIUREA A., SCHERER A., EXER P., BERNHARD J., DUDLER J., BEYELER B., et al. Tumor necrosis factor alpha inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum. 2013; 65(12):3096-106.

  • 2. LEIRISALO-REPO M., TURUNEN U., STENMAN S., HELENIUS P., SEPPALA K. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum. 1994; 37(1):23-31.

  • 3. DE KEYSER F., MIELANTS H. The gut in ankylosing spondylitis and other spondyloarthropathies: inflammation beneath the surface. J Rheumatol. 2003; 30(11):2306-7.

  • 4. DE KEYSER F., ELEWAUT D., DE VOS M., DE VLAM K., CUVELIER C., MIELANTS H., et al. Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am. 1998; 24(4):785-813, ix-x.

  • 5. BRADLEY J.R. TNF-mediated inflammatory disease. The Journal of Pathology. 2008; 214(2):149-60.

  • 6. BRAUN J., SIEPER J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin Biol Ther. 2003; 3(1):141-68.

  • 7. VAN DULLEMEN H.M., VAN DEVENTER S.J., HOMMES D.W., BIJL H.A., JANSEN J., TYTGAT G.N., et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995; 109(1):129-35.

  • 8. D’HAENS G., VAN DEVENTER S., VAN HOGEZAND R., CHALMERS D., KOTHE C., BAERT F., et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology. 1999; 116(5):1029-34.

  • 9. FORD A.C., SANDBORN W.J., KHAN K.J., HANAUER S.B., TALLEY N.J., MOAYYEDI P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106(4):644-59, quiz 60.

  • 10. JARNEROT G., HERTERVIG E., FRIIS-LIBY I., BLOMQUIST L., KARLEN P., GRANNO C., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005; 128(7):1805-11.

  • 11. SONG I.H., PODDUBNYY D.A., RUDWALEIT M., SIEPER J. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2008; 58(4):929-38.

  • 12. WATANABE T., TANIGAWA T., SHIBA M., NADATANI Y., NAGAMI Y., SUGIMORI S., et al. Anti-tumour necrosis factor agents reduce non-steroidal anti-inflammatory drug-induced small bowel injury in rheumatoid arthritis patients. Gut. 2014; 63(3):409-14.

  • 13. MAIDEN L., THJODLEIFSSON B., THEODORS A., GONZALEZ J., BJARNASON I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005; 128(5):1172-8.

  • 14. WATANABE T., TANIGAWA T., NADATANI Y., OTANI K., MACHIDA H., OKAZAKI H., et al. Mitochondrial disorders in NSAIDs-induced small bowel injury. J Clin Biochem Nutr. 2011; 48(2):117-21.

  • 15. BABB R.R. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs. West J Med. 1992; 157(4):444-7.

  • 16. SIGTHORSSON G., TIBBLE J., HAYLLAR J., MENZIES I., MACPHERSON A., MOOTS R., et al. Intestinal permeability and inflammation in patients on NSAIDs. Gut. 1998; 43(4):506-11.

  • 17. APPLEYARD C.B., MCCAFFERTY D.M., TIGLEY A.W., SWAIN M.G., WALLACE J.L. Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am J Physiol. 1996; 270(1 Pt 1):G42-8.

  • 18. CICCIA F., RIZZO A., TRIOLO G. Subclinical gut inflammation in ankylosing spondylitis. Curr Opin Rheumatol. 2016; 28(1):89-96.

  • 19. GRALNEK I.M., DEFRANCHIS R., SEIDMAN E., LEIGHTON J.A., LEGNANI P., LEWIS B.S. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther. 2008; 27(2):146-54.

  • 20. ORLANDO A., RENNA S., PERRICONE G., COTTONE M. Gastrointestinal lesions associated with spondyloarthropathies. World J Gastroenterol. 2009; 15(20):2443-8.

  • 21. DE KEYSER F., BAETEN D., VAN DEN BOSCH F., DE VOS M., CUVELIER C., MIELANTS H., et al. Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep. 2002; 4(6):525-32.

  • 22. MIELANTS H., DE KEYSER F., BAETEN D., VAN DEN BOSCH F. Gut inflammation in the spondyloarthropathies. Curr Rheumatol Rep. 2005; 7(3):188-94.

  • 23. ELEWAUT D. Linking Crohn’s Disease and Ankylosing Spondylitis: It’s All about Genes! PLoS Genet. 2010; 6(12).

  • 24. RUDWALEIT M., BAETEN D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006; 20(3):451-71.

  • 25. SENABRE-GALLEGO JÉ M., SANTOS-RAMÍREZ C., SANTOS-SOLER G., SALAS-HEREDIA E., SÁNCHEZ-BARRIOLUENGO M., BARBER X., et al. Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Patient Prefer Adherence. 2013; 7:961-72.

  • 26. VAN DEVENTER S.J. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn’s disease. Gastroenterology. 2001; 121(5):1242-6.

  • 27. GOLAN D.E., TASHJIAN A.H. Principles of pharmacology : the pathophysiologic basis of drug therapy. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012.

  • 28. VAN DEN BRANDE J.M.H., BRAAT H., VAN DEN BRINK G.R., VERSTEEG H.H., BAUER C.A., HOEDEMAEKER I., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology. 2003; 124(7):1774-85.

  • 29. MARZO-ORTEGA H., MCGONAGLE D., O’CONNOR P., EMERY P. Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Ann Rheum Dis. 2003; 62(1):74-6.

  • 30. KRUITHOF E., DE RYCKE L., ROTH J., MIELANTS H., VAN DEN BOSCH F., DE KEYSER F., et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum. 2005; 52(12):3898-909.

  • 31. VAN DER HEIJDE D., DIJKMANS B., GEUSENS P., SIEPER J., DEWOODY K., WILLIAMSON P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005; 52(2):582-91.

  • 32. KRUITHOF E., BAETEN D., VAN DEN BOSCH F., MIELANTS H., VEYS E.M., DE KEYSER F. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis. 2005; 64(4):529-36.

  • 33. BRAUN J., BARALIAKOS X., LISTING J., DAVIS J., VAN DER HEIJDE D., HAIBEL H., et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 2007; 57(4):639-47.

  • 34. PODDUBNYY D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet Dis. 2013; 5(1):45-54.

  • 35. MIELANTS H., VEYS E.M., DE VOS M., CUVELIER C., GOEMAERE S., DE CLERCQ L., et al. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol. 1995; 22(12):2266-72.

  • 36. MIELANTS H., VEYS E.M., CUVELIER C., DE VOS M., GOEMAERE S., DE CLERCQ L., et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol. 1995; 22(12):2279-84.

  • 37. MIELANTS H., VEYS E.M., CUVELIER C., DE VOS M., GOEMAERE S., DE CLERCQ L., et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol. 1995; 22(12):2273-8.

Journal Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 18 18 18
PDF Downloads 1 1 1